ArticleRMD open2018

Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study.

Marco Matucci-Cerinic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.